|
Patheon Launches Quick To MarketSM Program to Industry
Program introduces the “4•6•8 Promise”
TORONTO, Canada, (November 13, 2008) – Patheon (TSX:PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, will launch the new Quick To MarketSM program at the upcoming 2008 AAPS Conference in Atlanta, Georgia.
Quick To MarketSM is a unique Patheon-only program which offers accelerated transfer of commercially available products from an existing manufacturing plant to a plant within Patheon’s network. The program was formally established as a service within Patheon after excellent results and significant client satisfaction with recent rapid product transfers.
The Quick to MarketSM program supplements Patheon’s already established ‘Quick to ClinicSM’ program, which accelerates the development of early stage molecules at pre-clinical status and allows rapid distribution of drug product for use in Phase 1 clinical studies.
The Quick To MarketSM program also introduces its ‘4•6•8 Promise’. The term is used to highlight the benefits of its rapid development / rapid transfer programs by emphasizing to clients how quickly the work can be done by Patheon while maintaining the high standards of quality that Patheon is known for.
The ‘4•6•8 Promise’, as it is now called, is more adequately described as follows:
4: Quick To ClinicSM solid dose molecules will be formulated and ready for distribution to phase 1 clinical trials in just four months from receipt of API.
6: Quick To MarketSM solid dose or liquid products will be transferred and ready for regulatory filing in just six months from receipt of analytical methods and API. This enables clients to move products very quickly out of their plants and facilitate rationalization programs.
8: Quick To MarketSM aseptic liquid or lyophilized sterile products will be ready for regulatory filing in just eight months from receipt of analytical methods and API.
Wes Wheeler, CEO of Patheon Inc. stated: “The Quick To MarketSM and Quick To ClinicSM programs establish Patheon as a leader in accelerated development and product transfer. It is our way of demonstrating leadership in technical manufacturing and it highlights our legacy of quality to our customers. We are building a company based on superior product quality, ‘on-time, right first time’ delivery and personalized attention to customer’s demanding needs. We are enabling, constantly improving and tracking our performance through our global lean six sigma training program and our eProject Management system.”
ABOUT PATHEON
Patheon Inc. (TSX: PTI; www.patheon.com) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to more than 300 of the world’s leading pharmaceutical and biotechnology companies. Patheon’s services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, Liquid-Filled Hard Capsules and a variety of modified release technologies.
Patheon’s comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon’s Quick to ClinicSM programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API. Patheon’s integrated network strives to ensure that customer products can be launched with confidence globally.
Caution Concerning Forward-Looking Statements
This news release may contain forward-looking statements which reflect management’s expectations regarding the Company’s future growth of operations, performance (both operational and financial) and business prospects and opportunities. These statements are made in the context of the risks and uncertainties that are outlined in the Company’s public documents, which can be accessed on our website at www.patheon.com or on SEDAR at www.sedar.com.
Contacts:
|